Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Cancer Cell ; 39(11): 1497-1518.e11, 2021 11 08.
Article in English | MEDLINE | ID: mdl-34715028

ABSTRACT

ADAPTeR is a prospective, phase II study of nivolumab (anti-PD-1) in 15 treatment-naive patients (115 multiregion tumor samples) with metastatic clear cell renal cell carcinoma (ccRCC) aiming to understand the mechanism underpinning therapeutic response. Genomic analyses show no correlation between tumor molecular features and response, whereas ccRCC-specific human endogenous retrovirus expression indirectly correlates with clinical response. T cell receptor (TCR) analysis reveals a significantly higher number of expanded TCR clones pre-treatment in responders suggesting pre-existing immunity. Maintenance of highly similar clusters of TCRs post-treatment predict response, suggesting ongoing antigen engagement and survival of families of T cells likely recognizing the same antigens. In responders, nivolumab-bound CD8+ T cells are expanded and express GZMK/B. Our data suggest nivolumab drives both maintenance and replacement of previously expanded T cell clones, but only maintenance correlates with response. We hypothesize that maintenance and boosting of a pre-existing response is a key element of anti-PD-1 mode of action.


Subject(s)
Carcinoma, Renal Cell/drug therapy , Drug Resistance, Neoplasm , Immune Checkpoint Inhibitors/administration & dosage , Kidney Neoplasms/drug therapy , Nivolumab/administration & dosage , Receptors, Antigen, T-Cell/genetics , CD8-Positive T-Lymphocytes , Carcinoma, Renal Cell/genetics , Clinical Trials, Phase II as Topic , Endogenous Retroviruses/genetics , Gene Expression Profiling/methods , Genomics/methods , Humans , Immune Checkpoint Inhibitors/pharmacology , Kidney Neoplasms/genetics , Nivolumab/pharmacology , Prospective Studies , Sequence Analysis, RNA , Single-Cell Analysis , Tumor Escape , Tumor Microenvironment , Exome Sequencing
2.
Int J Exp Pathol ; 102(1): 45-50, 2021 02.
Article in English | MEDLINE | ID: mdl-32929772

ABSTRACT

Testing for the CALR mutation is included in the updated WHO criteria for essential thrombocythaemia (ET) and primary myelofibrosis (PMF). We report on the application of the CAL2 monoclonal antibody, raised against the mutated CALR gene to myeloid cases. The immunostain was used on 116 acute myeloid leukaemias (AML) and 66 myeloproliferative neoplasms (MPN) or myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN). None of AML cases was stained by the CAL2 antibody, while 20/66 MPNs and MDS/MPNs appeared positive. Fourteen of the latter cases were studied by molecular techniques, and all showed aberrations of the CALR gene. In addition, CAL2 positivity was found in some small-sized elements besides megakaryocytes. By double staining, these elements corresponded to small megakaryocytes as well as both erythroid and myeloid precursors. This finding suggests possible occurrence of CALR gene abnormalities in a stem cell.


Subject(s)
Antibodies, Monoclonal , Calreticulin/genetics , Myelodysplastic-Myeloproliferative Diseases/diagnosis , Myeloproliferative Disorders/diagnosis , Erythrocytes/metabolism , Granulocytes/metabolism , Humans , Megakaryocytes/metabolism , Mutation , Myelodysplastic-Myeloproliferative Diseases/genetics , Myeloproliferative Disorders/genetics
3.
Blood ; 134(17): 1415-1429, 2019 10 24.
Article in English | MEDLINE | ID: mdl-31501154

ABSTRACT

We investigated and modeled the mesenchymal stromal cell (MSC) niche in adult acute lymphoblastic leukemia (ALL). We used gene expression profiling, cytokine/chemokine quantification, flow cytometry, and a variety of imaging techniques to show that MSCs, directly isolated from the primary bone marrow specimens of patients with ALL, frequently adopted an activated, cancer-associated fibroblast phenotype. Normal, primary human MSCs and the MSC cell line HS27a both were activated de novo, when exposed to the reactive oxygen species (ROS)-inducing chemotherapy agents cytarabine (AraC) and daunorubicin (DNR), a phenomenon blocked by the antioxidant N-acetyl cysteine. Chemotherapy-activated HS27a cells were functionally evaluated in a coculture model with ALL targets. Activated MSCs prevented therapy-induced apoptosis and death in ALL targets, via mitochondrial transfer through tunneling nanotubes (TNTs). Reduction of mitochondrial transfer by selective mitochondrial depletion or interference with TNT formation by microtubule inhibitors, such as vincristine (VCR), prevented the "rescue" function of activated MSCs. Corticosteroids, also a mainstay of ALL therapy, prevented the activation of MSCs. We also demonstrated that AraC (but not VCR) induced activation of MSCs, mitochondrial transfer, and mitochondrial mass increase in a murine NSG model of disseminated SEM cell-derived ALL, wherein CD19+ cells closely associated with nestin+ MSCs after AraC, but not in the other conditions. Our data propose a readily clinically exploitable mechanism for improving treatment of ALL, in which traditional ROS-inducing chemotherapies are often ineffective at eradicating residual disease, despite efficiently killing the bulk population.


Subject(s)
Antineoplastic Agents/pharmacology , Mesenchymal Stem Cells/drug effects , Mitochondria/drug effects , Oxidative Stress/drug effects , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Adult , Aged , Animals , Antineoplastic Agents/therapeutic use , Cell Line, Tumor , Cells, Cultured , Coculture Techniques , Cytarabine/pharmacology , Cytarabine/therapeutic use , Daunorubicin/pharmacology , Daunorubicin/therapeutic use , Female , Humans , Male , Mesenchymal Stem Cells/metabolism , Mice , Middle Aged , Mitochondria/metabolism , Precursor Cell Lymphoblastic Leukemia-Lymphoma/metabolism , Young Adult
4.
Oncotarget ; 9(33): 22945-22959, 2018 05 01.
Article in English | MEDLINE | ID: mdl-29796164

ABSTRACT

Early oesophageal adenocarcinoma (OA) and pre-neoplastic dysplasia may be treated with endoscopic resection and ablative techniques such as photodynamic therapy (PDT). Though effective, discrete areas of disease may be missed leading to recurrence. PDT further suffers from the side effects of off-target photosensitivity. A tumour specific and light targeted therapeutic agent with optimised pharmacokinetics could be used to destroy residual cancerous cells left behind after resection. A small molecule antibody-photosensitizer conjugate was developed targeting human epidermal growth factor receptor 2 (HER2). This was tested in an in vivo mouse model of human OA using a xenograft flank model with clinically relevant low level HER2 expression and heterogeneity. In vitro we demonstrate selective binding of the conjugate to tumour versus normal tissue. Light dependent cytotoxicity of the phototherapy agent in vitro was observed. In an in vivo OA mouse xenograft model the phototherapy agent had desirable pharmacokinetic properties for tumour uptake and blood clearance time. PDT treatment caused tumour growth arrest in all the tumours despite the tumours having a clinically defined low/negative HER2 expression level. This new phototherapy agent shows therapeutic potential for treatment of both HER2 positive and borderline/negative OA.

5.
Int J Exp Pathol ; 99(1): 10-14, 2018 02.
Article in English | MEDLINE | ID: mdl-29473241

ABSTRACT

Non-dysplastic Barrett's oesophagus (NDBE) occurs as a consequence of an inflammatory response triggered through prolonged gastro-oesophageal reflux and it may precede the development of oesophageal adenocarcinoma. NF-κB activation as a result of the inflammatory response has been shown in NDBE, but the possible mechanism involved in the process is unknown. The aim of this study was to assess, using immunohistochemistry, Survivin and Bcl3 expression as potential biomarkers for NF-κB activation along the oesophageal metaplasia-dysplasia-adenocarcinoma sequence. Survivin is an NF-κB-inducible anti-apoptotic protein, and Bcl3 is a negative regulator of NF-κB. There was progressive upregulation of Survivin expression along the oesophageal metaplasia-dysplasia-adenocarcinoma sequence. Bcl3 expression was upregulated in non-dysplastic Barrett's oesophagus, low-grade, high-grade dysplasia and oesophageal adenocarcinoma when compared to squamous group. The study shows the differential expression of Bcl3 between the squamous and Barrett's stage, suggesting that Bcl3 could be a surrogate marker for early event involving constitutive NF-κB activation. In addition, the study suggests that NF-κB activation may infer resistance to apoptosis through the expression of anti-apoptotic genes such as Survivin, which showed progressive increase in expression throughout the oesophageal metaplasia-dysplasia-adenocarcinoma sequence. This ability to avoid apoptosis may underlie the persistence and malignant predisposition of Barrett's metaplasia.


Subject(s)
Adenocarcinoma/chemistry , Barrett Esophagus/metabolism , Biomarkers, Tumor/analysis , Cell Transformation, Neoplastic/chemistry , Esophageal Neoplasms/chemistry , Esophagus/chemistry , Immunohistochemistry , Inhibitor of Apoptosis Proteins/analysis , NF-kappa B/analysis , Proto-Oncogene Proteins/analysis , Transcription Factors/analysis , Adenocarcinoma/pathology , Adolescent , Adult , Aged , Aged, 80 and over , Apoptosis , B-Cell Lymphoma 3 Protein , Barrett Esophagus/pathology , Biopsy , Cell Transformation, Neoplastic/pathology , Esophageal Neoplasms/pathology , Esophagus/pathology , Female , Humans , Male , Metaplasia , Middle Aged , Signal Transduction , Survivin , Young Adult
6.
Oncotarget ; 8(15): 25080-25096, 2017 Apr 11.
Article in English | MEDLINE | ID: mdl-28212575

ABSTRACT

BACKGROUND: Mucin glycoprotein 1 (MUC1) is a glycosylated transmembrane protein on epithelial cells. We investigate MUC1 as a therapeutic target in Barrett's epithelium (BE) and esophageal adenocarcinoma (EA) and provide proof of concept for a light based therapy targeting MUC1. RESULTS: MUC1 was present in 21% and 30% of significantly enriched pathways comparing BE and EA to squamous epithelium respectively. MUC1 gene expression was x2.3 and x2.2 higher in BE (p=<0.001) and EA (p=0.03). MUC1 immunohistochemical expression increased during progression to EA and followed tumor invasion. HuHMFG1 based photosensitive antibody drug conjugates (ADC) showed cell internalization, MUC1 selective and light-dependent cytotoxicity (p=0.0006) and superior toxicity over photosensitizer alone (p=0.0022). METHODS: Gene set enrichment analysis (GSEA) evaluated pathways during BE and EA development and quantified MUC1 gene expression. Immunohistochemistry and flow cytometry evaluated the anti-MUC1 antibody HuHMFG1 in esophageal cells of varying pathological grade. Confocal microscopy examined HuHMFG1 internalization and HuHMFG1 ADCs were created to deliver a MUC1 targeted phototoxic payload. CONCLUSIONS: MUC1 is a promising target in EA. Molecular and light based targeting of MUC1 with a photosensitive ADC is effective in vitro and after development may enable treatment of locoregional tumors endoscopically.


Subject(s)
Adenocarcinoma/genetics , Antineoplastic Agents, Immunological/pharmacology , Esophageal Neoplasms/genetics , Gene Expression Regulation, Neoplastic/drug effects , Immunoconjugates/pharmacology , Light , Mucin-1/genetics , Adenocarcinoma/drug therapy , Adenocarcinoma/metabolism , Adenocarcinoma/pathology , Biomarkers , Cell Line, Tumor , Cell Survival/drug effects , Computational Biology , Disease Progression , Esophageal Neoplasms/drug therapy , Esophageal Neoplasms/metabolism , Esophageal Neoplasms/pathology , Gene Expression Profiling , Glycoproteins/genetics , Glycoproteins/metabolism , Humans , Immunohistochemistry , Mucin-1/metabolism , Neoplasm Grading , Neoplasm Metastasis
7.
Nat Commun ; 7: 12072, 2016 07 05.
Article in English | MEDLINE | ID: mdl-27377421

ABSTRACT

Synchronous colorectal cancers (syCRCs) are physically separated tumours that develop simultaneously. To understand how the genetic and environmental background influences the development of multiple tumours, here we conduct a comparative analysis of 20 syCRCs from 10 patients. We show that syCRCs have independent genetic origins, acquire dissimilar somatic alterations, and have different clone composition. This inter- and intratumour heterogeneity must be considered in the selection of therapy and in the monitoring of resistance. SyCRC patients show a higher occurrence of inherited damaging mutations in immune-related genes compared to patients with solitary colorectal cancer and to healthy individuals from the 1,000 Genomes Project. Moreover, they have a different composition of immune cell populations in tumour and normal mucosa, and transcriptional differences in immune-related biological processes. This suggests an environmental field effect that promotes multiple tumours likely in the background of inflammation.


Subject(s)
Colorectal Neoplasms/genetics , Genetic Heterogeneity , Germ-Line Mutation , Neoplasm Proteins/genetics , Neoplasms, Multiple Primary/genetics , Adult , Aged , Aged, 80 and over , Case-Control Studies , Clone Cells , Colorectal Neoplasms/immunology , Colorectal Neoplasms/pathology , Cytokines/genetics , Cytokines/immunology , Female , Genetic Predisposition to Disease , High-Throughput Nucleotide Sequencing , Humans , Male , Neoplasm Proteins/immunology , Neoplasms, Multiple Primary/immunology , Neoplasms, Multiple Primary/pathology , Receptors, Antigen, T-Cell/genetics , Receptors, Antigen, T-Cell/immunology , Toll-Like Receptors/genetics , Toll-Like Receptors/immunology
8.
J Cutan Pathol ; 41(3): 308-15, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24345188

ABSTRACT

Glomuvenous malformations (OMIM 138000) are hamartomas presenting in childhood as multiple, bluish papules and nodules in the skin, which are characterized histopathologically by irregular vascular spaces surrounded by typical glomus cells. Glomuvenous malformations are caused by autosomal dominant mutations of the GLMN gene. A 34-year-old woman and her 16-year-old son presented with bluish papules and nodules since childhood. Biopsy specimens from both patients showed histopathologic features of glomuvenous malformations, unusually in consistent and close association with smooth muscle, hair follicles and eccrine glands. Sequencing of the GLMN gene revealed the p.C36X (c.108C>A) mutation in germline DNA from both patients. This is probably the first report describing the hamartomatous features of familial glomuvenous malformations consistently associated with a prominent smooth muscle component and eccrine glands.


Subject(s)
Adaptor Proteins, Signal Transducing , Eccrine Glands , Germ-Line Mutation , Glomus Tumor , Muscle, Smooth , Skin Neoplasms , Adaptor Proteins, Signal Transducing/genetics , Adaptor Proteins, Signal Transducing/metabolism , Adolescent , Adult , Eccrine Glands/metabolism , Eccrine Glands/pathology , Female , Glomus Tumor/genetics , Glomus Tumor/metabolism , Glomus Tumor/pathology , Hair Follicle/metabolism , Hair Follicle/pathology , Humans , Male , Muscle, Smooth/metabolism , Muscle, Smooth/pathology , Skin Neoplasms/genetics , Skin Neoplasms/metabolism , Skin Neoplasms/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...